ALTAIRA
LIVE

Serial Number

99505429

Owner

Nortiva Bio, Inc.

Attorney

Keith Toms

Filing Date

Nov 19, 2025

Add to watchlist:

No watchlists yet
View on USPTO

ALTAIRA Trademark

Serial Number: 99505429

ALTAIRA is a trademark filed by Nortiva Bio, Inc. on November 19, 2025. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Nortiva Bio, Inc. (2 trademarks)

930 Winter Street, Suite 1500
Waltham, MA 02451

Entity Type: 03

Trademark Details

Filing Date

November 19, 2025

Registration Date

Not Registered

Goods & Services

Pharmaceutical research and development; Scientific research; Medical research; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development of technology in the field of drug delivery; Research and development of technology in the field of long-acting, extended release, and continuous release drug delivery agents; Research and development of technology that facilitate the delivery of pharmaceutical preparations in the field of capsules, pills, ingestible flexible stars, ingestible arm-and-hub delivery platforms contained in capsules, dissolvable films, and coatings; Pharmaceutical research in the field of drug delivery agents; Pharmaceutical research in the field of capsules, pills, ingestible flexible stars, dissolvable films, and coatings that facilitate the delivery of pharmaceutical preparations; Pharmaceutical research in the field of excipients and pharmaceutical formulation; Pharmaceutical research in the field of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical research in the field of antibiotics, infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical research in the field of schizophrenia, bipolar disorder, cardiovascular disease, cardiometabolic disease, addiction, malaria, infectious diseases, septic shock, hypotension; Medical and scientific research in the field of drug delivery agents; Medical and scientific research in the field of capsules, pills, ingestible flexible stars, dissolvable films, and coatings that facilitate the delivery of pharmaceutical preparations; Medical and scientific research in the field of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Medical and scientific research in the field of antibiotics, infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Medical and scientific research in the fields of organ rejection and immunosuppressants; Medical and scientific research in the field of excipients and pharmaceutical formulation; Medical and scientific research in the field of schizophrenia, bipolar disorder, cardiovascular disease, cardiometabolic disease, addiction, malaria, infectious diseases, septic shock, hypotension; Consulting services in the field of pharmaceutical research

Excipients for use in the manufacture of pharmaceutical preparations; Chemical additives for use in the manufacture of pharmaceutical preparations; Active chemical ingredients for use in the manufacture of pharmaceuticals

Drug delivery agents in the form of capsules, pills, ingestible flexible stars, ingestible arm-and-hub delivery platforms contained in capsules, dissolvable films, and coatings that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of long-acting, extended release, or continuous release capsules, pills, ingestible flexible stars, ingestible arm-and-hub delivery platforms contained in capsules, dissolvable films, and coatings that facilitate the delivery of pharmaceutical preparations; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of organ rejection, namely, immunosuppressants; Pharmaceutical preparations for the treatment of schizophrenia, bipolar disorder, cardiovascular disease, cardiometabolic disease, addiction, malaria, infectious diseases, septic shock, hypotension; Antibiotics; Pharmaceutical preparations used in organ transplantation; Contraceptive preparations

Filing History

APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 12, 2026 CNSA
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jun 10, 2026 GNEN
EXAMINER'S AMENDMENT ENTERED
Jun 10, 2026 XAEC
EXAMINERS AMENDMENT E-MAILED
Jun 10, 2026 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jun 10, 2026 CNEA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Jun 10, 2026 ZZZX
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 3, 2026 CNSA
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jun 1, 2026 GNEN
EXAMINER'S AMENDMENT ENTERED
Jun 1, 2026 XAEC
EXAMINERS AMENDMENT E-MAILED
Jun 1, 2026 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jun 1, 2026 CNEA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 2, 2026 GNRN
NON-FINAL ACTION E-MAILED
Apr 2, 2026 GNRT
NON-FINAL ACTION WRITTEN
Apr 2, 2026 CNRT
ASSIGNED TO EXAMINER
Mar 26, 2026 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 12, 2026 NWOS
APPLICATION FILING RECEIPT MAILED
Nov 19, 2025 MAFR
NEW APPLICATION ENTERED
Nov 19, 2025 NWAP